References

mrj

Современная ревматология

Modern Rheumatology Journal

1996-70122310-158X

IMA-PRESS, LLC

10.14412/1996-7012-2012-716

mrj-401

Research Article

Статьи

Articles

Искусство лечения остеопороза: бисфосфонаты

The art of treating osteoporosis: Bisphosphonates

Мазуренко

С. О.

Mazurenko

Sergey Olegovich

dr_mazurenko@mail.ru

2012

09032012

№1 (2012)

4956

2012

Мазуренко С.О.

Mazurenko S.O.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://mrj.ima-press.net/mrj/article/view/401

References1

<div>NIH Consensus Development Conference on Osteoporosis: Prevention, Diagnosis and Therapy. JAMA 2000; 287: 785—95.Russell R.G. Bisphosphonates: the first 40 years. Bone 2011; 49(1): 2—19.Blomen L.J.M.J. History of the bisphosphonates: discovery and history of the nonmedical uses of bisphosphonates. In: Bijvoet O.L.M., Fleisch H.A., Canfield R.E., Russell R.G.G. (ed.). Bisphosponate on Bones. Amsterdam: Elsevier, 1995; 111—24.Russell R.G.G. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci 2006; 1068: 367—401.McClung M.R. Bisphosphonates. Endocrinol Metab Clin North Am 2003; 32: 253—71.Bergstrom J.D., Bostedor R.G., Masarachia P.J. et al. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000; 373: 231—41.Luckman S.P., Hughes D.E., Coxon F.P. et al. Nitrogen-containing bisphosphonates inhibit mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13: 581—9.Boonekamp P.M., van der Wee-Pals L.J.A., van Wijk—van Lennep M.L.L. et al. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1986; 1: 27—39.Lowik C.W.G.M., van der Pluijm G., van der Wee-Pals L.J.A. et al. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. J Bone Miner Res 1988; 3: 185—92.Plotkin L.I., Weinstein R.S., Parfitt A.M. et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999; 104: 1363—74.Russell R.G., Watts N.B., Ebetino F.H. et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19: 733—59.Russell R.G.G. Bisphosphonates: Mode of Action and Pharmacology. Pediatrics 2007; 119(Suppl.): S150—S162.Green J.R., Mueller K., Jaeggi K.A. Preclinical pharmacology of CGP42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 745—51.Raisz L.G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005; 115: 3318—25.Seeman E., Delmas P.D. Bone quality — the material and structural basis of bone strength and fragility. N Engl J Med 2006; 354: 2250—61.Khosla S. Pathogenesis of osteoporosis. In: Robertson R.P. (ed.). Translational endocrinology & metabolism: osteoporosis update. Chevy Chase: The Endocrine Society 2010; 55—86.Остеопороз. Диагностика, профилактика и лечение. Под ред. О.М. Лесняк, Л.И. Беневоленской. 2-е изд. М.: ГЭОТАР-Медиа, 2009; 272 с.Camacho P., Miller P. Pathogenesis. In: Osteoporosis: A Guide for Clinicians. Philadelphia PA: Lippincott, Williams and Wilkins, 2007; 226.Black D.M., Cummings S.R., Karpf D.B. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535—41.Cummings S.R., Black D.M., Thompson D.E. et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077—82.Bone H., Hosling D., Devogelaer J.P. et al. Ten yearsX experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189—99.Reginster J., Minne H.W., Sorensen O.H. et al. Randomized trial of the effects of rise-dronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11: 83—91.McClung M.R., Geusens P., Miller P.D. et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333—40.Chestnut C.H. III, Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241—9.Black D.M., Delmas P.D., Eastell R. et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809—22.Compston J. Treatments for osteoporosis — looking beyond the HORIZON (editorial). N Engl J Med 2007; 356: 1878—80.Clunie G., Keen R. Osteoporosis. Oxford University Press, 2007; 208.Binkley N. Osteoporosis in men. Arq Bras Endocrin Metab 2006; 50: 764—74.Orwoll E., Ettinger M., Weiss S. et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604—10.Sato Y., Iwamoto J., Kanoko T. et al. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 2005; 165: 1743—8.Lyles K.W., Colon-Emeric C.S., Magaziner J.S. et al. Zoledronic acid in reducing clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357: 1799—809.Weinstein R.S., Jilka R.L., Parfitt A.M. et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effects on bone. J Clin Invest 1998; 102: 274—82.O'Brien C.A., Jia D., Plotkin L.I. et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004; 145: 1835—41.Seeman E., Delmas P.D. Bone quality — the material and structural basis of bone strength and fragility. N Engl J Med 2006; 354: 2250—61.Jia D., O'Brien C.A., Stewart S.A. et al. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 2006; 147: 5592—9.Adler R.A., Curtis J.R., Saag K. et al. Glucocorticoid-induced osteoporosis. In: Marcus R., Feldman D., Nelsen D.A., Rosen C.J. (ed.). Osteoporosis. 3rd ed. San Diego, CA: Elsevier-Academic Press, 2008; 1135—66.Adachi J.D., Saag K.G., Delmas P.D. et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthr Rheum 2001; 44: 202—11.Reid D.M., Hughes R.A., Laan R.F. et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000; 15: 1006—13.Reid D.M., Devogelaer J.-P., Saag K. et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009; 373: 1253—63.Devogelaer J.-P., Goemaere S., Boonen S. et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteopor Int 2006; 17: 8—19.Eastell R., Reid D.M., Compston J. et al. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 1998; 2446271—92.Nishimura J., Ikuyama S. Glucocorticoid-induced osteoporosis: pathogenesis and management. J Bone Miner Metab 2000; 18: 350—2.Weinstein R.S. Glucocorticoid-Induced Bone Disease. N Engl J Med 2011; 365: 62—70.Emkey R., Delmas P.D., Goemaere S. et al. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study. Arthr Rheum 2003; 48: 1102—8.Boonen S., Autier P., Barette M. et al. Functional outcome and quality of life following hip fracture in elderly women: a one-year prospective controlled study. Osteopor Int 2004; 15: 87—94.Adachi J.D., Ioannidis G., Berger C. et al. The influence of osteoporotic fractures on health related quality of life in community-dwelling men and women across Canada. Osteopor Int 2001; 12: 903—8.Magaziner J., Lydick E., Hawkes W. et al. Excess mortality attributable to hip fracture in white women aged 70 years and older. Am J Public Health 1997; 87: 1630—6.Hannan E.L., Magaziner J., Wang J.J. et al. Mortality and locomotion 6 months after hospitalization for hip fracture: risk factors and risk-adjusted hospital outcomes. JAMA 2001; 285: 2736—42.Davidson C.W., Merrilees M.J. Wilkinson T.J. et al. Hip fracture mortality and morbidity — can we do better? N Z Med J 2001; 114: 329—32.Colon-Emeric C., Kuchibhatla M., Pieper C. et al. The contribution of hip fracture to risk of subsequent fracture: data from two longitudinal studies. Osteopor Int 2003; 14: 879—83.Lyles K.W., Colоn-Emeric C.S., Magaziner J.S. et al. Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. N Engl J Med 2007; 357: 1799—809.Kamel H.K., Hussain M.S., Tariq S. et al. Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. Am J Med 2000; 109: 326—8.Kiebzak G.M., Beinart G.A., Perser K. et al. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002; 162: 2217—22.Lyles K.W., Cokrn-Emeric C.S., Magaziner J.S. et al. Zolendronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357: 1799—809.Colon-Emeric C., Nordsletten L., Olson S. et al. Association between timing of zoledronic acid infusion and hip fracture healing. Osteopor Int 2011; 22: 2329—36.Мазуренко С.О. Метаболические заболевания костей. Диагностика и лечение. СПб.: Изд-во С.-Петербургского унта, 2007; 48 с.Ribeiro A., DeVault K.R., Wolfe J.T. III. et al. Alendronate-associated esophagitis: endoscopic and pathologic features. Gastrointest Endosc 1998; 47: 525—8.Holick M.F.. Vitamin D deficiency. N Engl J Med 2007; 357: 266—81.Tang B.M., Eslick G.D., Nowson C. et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007; 370(9588): 657—66.Bilezikian J.P. Osteonecrosis of the jaw — do bisphosphonates pose a risk? N Engl J Med 2006; 355: 2278—81.Мазуренко С.О. Диагностика и лечение остеопороза в общей клинической практике. Рук-во для врачей. СПб.: Изд-во С.-Петербургского ун-та, 2010; 56 с.Lewiecki E.M., Miller P.D. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Exp Opin Drug Saf 2007; 6: 663—72.Boonen S., Sellmeyer D.E., Lippuner K. et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 2008; 74: 641—8.Fleisch H. Bisphosphonates in bone dis ease: from the laboratory to the patient. 4th ed. San Diego, CA: Academic Press, 2000; 42.Grossman J.M., Gordon R., Ranganath V.K. et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthr Care Res (Hoboken) 2010; 62: 1515—26.McClung M., Miller P., Recknor C. et al. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol 2009; 114: 999—1007.Huybrechts K.F., Ishak K.J., Caro J.J. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006; 38: 922—8.Siris E.S., Harris S.T., Rosen C.J. et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81: 1013—22.Strampel W., Emkey R., Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 2007; 30: 755—63.Odvina C.V., Zerwekh J.E., Rao D.S. et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrin Metab 2005; 90: 1294—301.Stepan J.J., Burr D.B., Pavo I. et al. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 2007; 41: 378—85.Recker R.R., Delmas P.D., Halse J. et al. Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure. J Bone Min Res 2008; 23: 6—16.Park-Wyllie L.Y., Mamdani M.M., Juurlink D.N. et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011; 305: 783—9.Shane E., Burr D., Ebeling P.R. et al. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research. J Bone Min Res 2010; 25: 2267—94.Watts N.B., Bilezikian J.P., Camacho P.M. et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocrinol Pract 2010; 16(Suppl. 3): S1—S37.Lyles K.W., Colon-Emeric C.S., Magaziner J.S. et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357: 1799—809.Sambrook P.N., Cameron I.D., Chen J.S. et al. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteopor Int 2011; 22: 2551—6.</div>

The authors declare that there are no conflicts of interest present.